Clinical Trial Update: Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy trial of tulisokibart (MK-7240/PRA023) for diffuse cutaneous systemic sclerosis-associated interstitial lung disease is ongoing and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Interstitial Lung Disease
• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• Tulisokibart

Snippet

Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Diffuse Cutaneous Systemic Sclerosis, Interstitial Lung Disease | Phase 2 | Status: ACTIVE_NOT_RECRUITING